Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Other Non Operating Income: 2023-2024

Historic Other Non Operating Income for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $1.0 million.

  • Contineum Therapeutics' Other Non Operating Income rose 2512.77% to $1.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.0 million, marking a year-over-year increase of 674.58%. This contributed to the annual value of $1.0 million for FY2024, which is 675.14% up from last year.
  • Per Contineum Therapeutics' latest filing, its Other Non Operating Income stood at $1.0 million for FY2024, which was up 675.14% from -$177,000 recorded in FY2023.
  • In the past 5 years, Contineum Therapeutics' Other Non Operating Income registered a high of $1.0 million during FY2024, and its lowest value of -$177,000 during FY2023.
  • Its 2-year average for Other Non Operating Income is $420,500, with a median of $420,500 in 2023.
  • Data for Contineum Therapeutics' Other Non Operating Income shows a peak YoY spiked of 675.14% (in 2024) over the last 5 years.
  • Contineum Therapeutics' Other Non Operating Income (Yearly) stood at -$177,000 in 2023, then soared by 675.14% to $1.0 million in 2024.